Baker D - Search Results

1

A Multi-site In-depth Evaluation of the Quanterix Simoa from a User's Perspective.

Chunyk AG, Joyce A, Fischer SK, Dysinger M, Mikulskis A, Jeromin A, Lawrence-Henderson R, Baker D, Yeung D. Chunyk AG, et al. Among authors: baker d. AAPS J. 2017 Dec 1;20(1):10. doi: 10.1208/s12248-017-0156-7. AAPS J. 2017. PMID: 29196830

2

When assay format matters: a case study on the evaluation of three assay formats to support a clinical pharmacokinetic study.

Peng K, Baker D, Brignoli S, Cabuhat J, Fischer SK. Peng K, et al. Among authors: baker d. AAPS J. 2014 Jul;16(4):625-33. doi: 10.1208/s12248-014-9594-7. Epub 2014 Apr 22. AAPS J. 2014. PMID: 24752719 Free PMC article.

3

Evaluation of IgE Antibodies to Omalizumab (Xolair®) and Their Potential Correlation to Anaphylaxis.

Baker DL, Nakamura GR, Lowman HB, Fischer SK. Baker DL, et al. AAPS J. 2016 Jan;18(1):115-23. doi: 10.1208/s12248-015-9821-x. Epub 2015 Sep 4. AAPS J. 2016. PMID: 26340860 Free PMC article.

4

Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood.

Hendricks R, Baker D, Brumm J, Davancaze T, Harp C, Herman A, Büdingen HV, Townsend M, Fischer SK. Hendricks R, et al. Among authors: baker d. Bioanalysis. 2019 Aug;11(15):1405-1418. doi: 10.4155/bio-2019-0163. Epub 2019 Aug 12. Bioanalysis. 2019. PMID: 31401845

5

Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy.

Baker DL, Peng K, Cheu M, Fischer SK. Baker DL, et al. Curr Med Res Opin. 2014 May;30(5):913-22. doi: 10.1185/03007995.2013.877435. Epub 2014 Jan 24. Curr Med Res Opin. 2014. PMID: 24354863 Clinical Trial.

6

Response to Becher and Strohner comment regarding Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. CMRO 2014;30:913-22.

Baker DL, Peng K, Cheu M, Fischer SK. Baker DL, et al. Curr Med Res Opin. 2014 Oct;30(10):1927-9. doi: 10.1185/03007995.2014.938150. Epub 2014 Jul 7. Curr Med Res Opin. 2014. PMID: 24960148 No abstract available.

7

Colorimetric determination of DNase I activity with a DNA-methyl green substrate.

Sinicropi D, Baker DL, Prince WS, Shiffer K, Shak S. Sinicropi D, et al. Among authors: baker dl. Anal Biochem. 1994 Nov 1;222(2):351-8. doi: 10.1006/abio.1994.1502. Anal Biochem. 1994. PMID: 7864358

8

An antibody capture bioassay (ACB) for DNase in human serum samples.

Gibson UE, Chen AB, Baker DL, Sinicropi DV. Gibson UE, et al. Among authors: baker dl. J Immunol Methods. 1992 Nov 5;155(2):249-56. doi: 10.1016/0022-1759(92)90292-2. J Immunol Methods. 1992. PMID: 1431153

9

Improved potency of hyperactive and actin-resistant human DNase I variants for treatment of cystic fibrosis and systemic lupus erythematosus.

Pan CQ, Dodge TH, Baker DL, Prince WS, Sinicropi DV, Lazarus RA. Pan CQ, et al. Among authors: baker dl. J Biol Chem. 1998 Jul 17;273(29):18374-81. doi: 10.1074/jbc.273.29.18374. J Biol Chem. 1998. PMID: 9660804 Free article.

10

Pharmacodynamics of recombinant human DNase I in serum.

Prince WS, Baker DL, Dodge AH, Ahmed AE, Chestnut RW, Sinicropi DV. Prince WS, et al. Among authors: baker dl. Clin Exp Immunol. 1998 Aug;113(2):289-96. doi: 10.1046/j.1365-2249.1998.00647.x. Clin Exp Immunol. 1998. PMID: 9717980 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,770 results

Search Page

Filters